Moberg Pharma - Terclara is the market leader in both Sweden and Norway

Q2 confirms that Moberg’s Terclara is now the market leader in both Sweden and Norway. Consumer marketing activities and a strong channel presence have resulted in high market shares of 44% in Sweden (value) and 43% in Norway (value). The H1 2025 success is a good platform ahead of the expanded European Terclara launch in 2026.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/